title: International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.
abstract: A randomized, double blind, placebo controlled Phase I trial of a prototype human immunodeficiency virus type 1 (HIV-1) synthetic peptide vaccine was conducted in Bangkok, Thailand, to evaluate the safety and immunogenicity of the vaccine in a population of healthy adults at low risk for HIV infection, and to establish essential infrastructure for future HIV vaccine trials in Thailand. Thirty volunteers (25 males; 5 females) were recruited and randomized into 3 groups, receiving 3 intramuscular injections of either 100 micrograms vaccine (N = 12) or 500 micrograms vaccine (N = 12) or alum placebo (N = 6) on weeks 0, 4 and 25. The vaccine was well tolerated without any serious adverse effects. HIV-1 specific ELISA responses were detected in 20/24 subjects who received the vaccine, with V3 binding antibody titers ranging from 1:69 to 1:5,041. HIV-1 (MN) specific neutralizing antibody was detected in 19/20 of subjects with detectable HIV-1 specific binding antibody. Neutralization titers ranged from 1:14 to 1:1,294, which were less than titers observed in HIV-infected subjects. The results of this study indicate that the vaccine was well tolerated, and that the vaccine stimulated anti-HIV humoral immune responses in Thai subjects. The successful undertaking of this first HIV vaccine trial conducted in Thailand provided important preparatory information surrounding volunteer recruitment and motivations, and paves the way for future trials of HIV vaccines in Thailand.
authors.affiliation: Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
authors.forename: P
authors.initials: P
authors.lastname: Phanuphak
authors.forename: S
authors.initials: S
authors.lastname: Teeratakulpixarn
authors.forename: S
authors.initials: S
authors.lastname: Sarangbin
authors.forename: S
authors.initials: S
authors.lastname: Nookhai
authors.forename: S
authors.initials: S
authors.lastname: Ubolyam
authors.forename: S
authors.initials: S
authors.lastname: Sirivichayakul
authors.forename: A
authors.initials: A
authors.lastname: Leesavan
authors.forename: B D
authors.initials: BD
authors.lastname: Forrest
authors.forename: C V
authors.initials: CV
authors.lastname: Hanson
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: C Y
authors.initials: CY
authors.lastname: Wang
authors.forename: W C
authors.initials: WC
authors.lastname: Koff
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000328:Adult; D000956:Antigens, Viral / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000956:Antigens, Viral; D010455:Peptides; D014614:Vaccines, Synthetic